Brief: Hyloris: Extension Of Maxigesic IV Footprint Into South America
06/05/2021 06:09
May 6 (Reuters) - HYLORIS PHARMACEUTICALS SA HYL.BR :
* ANNOUNCES THAT ITS PARTNER FOR MAXIGESIC IV, AFT
PHARMACEUTICALS
("AFT"), HAS EXTENDED ITS EXISTING LICENSE AND DISTRIBUTION
AGREEMENT WITH PHARMA BAVARIA INTERNATIONAL FOR
COMMERCIALISATION OF MAXIGESIC IV
* MARKET FOR PAIN MEDICINES IN LATIN AMERICA IS EXPECTED TO
GROW
AT AN AVERAGE ANNUAL RATE OF 3.5% UNTIL 2027
Source text for Eikon: ID:nGNEyW69v
Further company coverage: HYL.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million